PREMARIN significantly reduced the frequency of moderate to severe hot flashes vs placebo at weeks 4 and 12 at each dose studied (0.3 mg, 0.45 mg, and 0.625 mg)1
SD=standard deviation. All observed mean endpoints were statistically significant vs placebo, P<0.001.
In the Health and Osteoporosis, Progestin and Estrogen (HOPE) Study, a total of 2805 postmenopausal women (average age 53.3 ± 4.9 years) were randomly assigned to 1 of 8 treatment groups of either placebo or conjugated estrogens, with or without medroxyprogesterone acetate. Efficacy for vasomotor symptoms was assessed during the first 12 weeks of treatment in a subset of symptomatic women (n=241) who had at least 7 moderate to severe hot flashes daily, or at least 50 moderate to severe hot flashes during the week before randomization.1
  1. Premarin [prescribing information]. New York, NY: Pfizer Inc.; September 2018.